Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies—a meta-analysis

Guoliang Xiao  
the first people's hospital of Neijiang

Qiuxi Yang  
Hainan Medical University

Ziwei Bao  
Southwest Medical University

Haixia Mao  
Southwest Medical University

Yi Zhang (✉ 307910985@qq.com)  
First Peoples Hospital of Neijiang

Shibu Lin  
Hainan Medical University

Research article

Keywords: TRIM44; Protein; Prognosis; Clinicopathological features

Posted Date: May 1st, 2020

DOI: https://doi.org/10.21203/rs.3.rs-15897/v3

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at BMC Cancer on June 5th, 2020. See the published version at https://doi.org/10.1186/s12885-020-07014-w.
Abstract

Background: Previous researches have reported that tripartite motif-containing 44 (TRIM44) is related to the prognosis of multiple human tumors. This study was designed to systematically assess the prognostic value of TRIM44 in human malignancies and summarize its possible tumor-related mechanisms.

Methods: The available databases were searched for eligible studies that evaluated the clinicopathological and prognostic roles of TRIM44 in patients with malignancies. The hazard ratios (HR) and odds ratios (OR) were combined to assess the predictive role of TRIM44 using Stata/SE 14.1 software.

Results: A total of 1,740 patients from thirteen original studies were finally included in this study. The results of the combined analysis showed that over-expression of TRIM44 protein was significantly correlated with shorter overall survival (OS) (HR = 1.94, 95% CI: 1.60-2.35) and worse disease-free survival (DFS) (HR= 2.13, 95% CI: 1.24-3.65) in cancer patients. Additionally, the combined ORs indicated that elevated expression level of TRIM44 protein was significantly associated with lymph node metastasis (OR=2.69, 95% CI: 1.71-4.24), distant metastasis (OR=10.35, 95% CI: 1.01-106.24), poor tumor differentiation (OR=1.78, 95% CI: 1.03-3.09), increased depth of tumor invasion (OR=2.72, 95% CI: 1.73-4.30), advanced clinical stage (OR=2.75, 95% CI: 2.04-3.71), and recurrence (OR=2.30, 95% CI: 1.34-3.95). Furthermore, analysis results using Gene Expression Profiling Interactive Analysis (GEPIA) showed that the expression level of TRIM44 mRNA was higher in most tumor tissues than in the corresponding normal tissues, and the relationship between TRIM44 mRNA level and prognosis in various malignant tumors also explored in GEPIA and OS analysis webservers.

Conclusions: TRIM44 may serve as a valuable prognostic biomarker and a potential therapeutic target for patients with malignancies.

Background

Malignant cancers are one of the main causes of disease-related death in the world. Advances in detection techniques have contributed to the discovery of early cancer, and the progress of perioperative treatment has reduced the mortality in patients with malignancies. However, after standard treatment, patients with advanced malignancies still show poor survival rates due to consequent recurrence or metastasis. Due to the ongoing intensive cancer research, the precise tumor-related mechanisms have gradually been understood and an increasing number of therapeutic targets have been identified.

The field is moving toward targeted therapy as a primary form of tumor therapy. Therefore, major efforts have been made to identify molecular markers that predict the prognosis. More importantly, these markers can often be used as therapeutic targets, and then the corresponding targeted drug design can be carried out. Compared with gene therapy, the current targeted drug design for functional proteins may be more conducive to bringing new progress in tumor therapy.

Recent studies have shown that some tripartite motif (TRIM) proteins are involved in tumorigenesis and progression, and they function as protein regulators, and involve in important intersections in the gene pathways [1]. Tripartite motif-containing 44 (TRIM44) localized in the cytoplasmic compartment of cells was reported to contribute to diverse pathological conditions, such as tumors, growth disorders, and neurodegeneration [2-6]. TRIM44 protein has a zinc-finger domain, which plays the role of ubiquitin-specific proteases (USPs). Thus, it has been defined as the "USP-like" TRIM [6]. The ubiquitin–proteasome system plays an important role in the regulation of cell function and is the intersection of multiple regulatory pathways [7]. TRIM44 is an atypical TRIM-family protein that lacks the RING-finger domain but contains a zinc-finger domain that is often found in ubiquitin-specific proteases[8].

Some studies have suggested that TRIM44 plays a cancer-promoting role in oncogenesis and tumor progression, and increased TRIM44 expression was detected in cancer tissues and it was associated with poor prognosis and advanced clinicopathological parameters [9-11]. Importantly, recent studies have revealed that high levels of TRIM44 induce the epithelial-to-mesenchymal transition (EMT) in cancer cells and that TRIM44 promotes tumor initiation and progression by activating the PI3K/AKT/mTOR pathway [10,12]. Another report indicated that TRIM44 could activate the NF-κB pathway to promote lung cancer cell migration and invasion [13].

However, to date, no specific meta-analysis has been performed to evaluate the association between TRIM44 expression and clinical outcomes in diverse malignancies. Therefore, we conducted this study to provide a systematic evaluation of the predictive value of TRIM44 and explore its feasibility as a new therapeutic target.

Methods
**Search strategy**

A comprehensive search strategy was conducted in the following databases: Web of Science, PubMed, CNKI, Wanfang, EMBASE, and Google Scholar. The search deadline was November 2, 2019. The following keywords were adopted according to the retrieval strategy: “Tripartite motif-containing 44” OR “TRIM44”; “cancer” OR “tumor” OR “carcinoma” OR “malignancy.”

**Inclusion and exclusion criteria**

Inclusion criteria were as follows: 1) The expression of TRIM44 protein was measured in tissue samples from primary solid cancers; 2) All patients included in the original studies were divided into two groups according to the expression levels of TRIM44 protein; 3) The hazard ratio (HR) of survival outcomes or clinicopathological data based on the high and low levels of TRIM44 protein expression was reported; 4) The survival curve presented or sufficient data were available for calculating the HR with 95% CI.

Exclusion criteria were as follows: not original studies, studies without a control group, articles that only explored the molecular functions of TRIM44, and studies with less than 50 cases.

**Data extraction**

For each study, the following general information was independently collected by two investigators (ZW B and HX M): author’s name, number of patients, cancer type, high expression rate, end-points (analysis type), evaluation standard of TRIM44 overexpression, follow-up time, detection method, and outcome measures.

Additionally, information on the clinicopathological parameters related to tumor progression was collected. For survival data extraction, the HRs and 95% CIs were directly used from the multivariate survival analysis or the univariate analysis second priority; otherwise, they were retrieved using the Engauge Digitizer version 4.1 if a study only provided Kaplan-Meier curves.

**Quality assessment**

Newcastle-Ottawa quality assessment scale (NOS) was adopted to evaluate the quality of enrolled studies. This method comprised three parameters of quality: selection (score: 0-4), comparability (score: 0-2), and outcome assessment (score: 0-3), with total scores ranging from 0-9 [14]. The study with total scores greater than 6 was considered high quality in the present meta-analysis.

**Public data and tools**

In this study, the Gene Expression Profiling Interactive Analysis (GEPIA) database ([http://geopia.cancer-pku.cn/](http://geopia.cancer-pku.cn/)), an online database containing RNA expression information and survival data from the TCGA and the GTEx projects, was utilized [15]. This database consists of 33 different types of human malignant tumors, including ACC (Adrenocortical carcinoma), BLCA (Bladder urothelial carcinoma), BRCA (Breast invasive carcinoma), CESC (Cervical squamous cell carcinoma and endocervical adenocarcinoma), CHOL (Cholangio carcinoma), COAD (Colon adenocarcinoma), DLBC (Lymphoid neoplasm diffuse large B-cell lymphoma), ESCA (Esophageal carcinoma), GBM (Glioblastoma multiforme), HNSC (Head and neck squamous cell carcinoma), KICH (Kidney chromophobe), KIRC (Kidney renal clear cell carcinoma), KIRP (Kidney renal papillary cell carcinoma), LAML (Acute myeloid leukemia), LGG (Brain lower grade glioma), LIHC (Liver hepatocellular carcinoma), LUAD (Lung adenocarcinoma), LUSC (Lung squamous cell carcinoma), MESO (Mesothelioma), OV (Ovarian serous cystadenocarcinoma), PAA (Pancreatic adenocarcinoma), PCPG (Pheochromocytoma and parangangioma), PRAD (Prostate adenocarcinoma), READ (Rectum adenocarcinoma), SARC (Sarcoma), SKCM (Skin cutaneous melanoma), STAD (Stomach adenocarcinoma), TGCT (Testicular germ cell tumors), THCA (Thyroid carcinoma), THYM (Thymoma), UCEC (Uterine corpus endometrial carcinoma), UCS (Uterine carcinosarcoma) and UVM (Uveal melanoma).

Here, GEPIA was used to show the expression level and the prognostic value of TRIM44 in various human cancers. A box plot was used to represent the RNA expression level in samples. And patients were divided into high-expression and low-expression groups according to the median expression level of TRIM44, and the Kaplan-Meier plots for survival analysis were performed.

Besides, the prognostic value of TRIM44 in the specific type of cancer was explored by some online OS analysis webservers, including OSgbm for glioblastoma [16], OSpaad for pancreatic carcinoma [17], OSbrca for breast cancer [18], OSacc for adrenocortical
cancer [19], OSUvm for uveal melanoma [20], OScc for cervical cancer [21], OSkirc for kidney renal clear cell carcinoma [22], OSescc for esophageal squamous cell carcinoma [23], OSblca for bladder cancer [24], OSlms for leiomyosarcoma [25].

Statistical analysis

STATA/SE 14.1 was used to analyze the relationship between TRIM44 expression and prognosis as well as the clinicopathological features in human cancers. $I^2$ statistics and Chi-square Q test were adopted to estimate the heterogeneity among enrolled studies. The random-effects model was adopted to conduct the meta-analysis with significant heterogeneity ($I^2 \geq 50\%$ or $P_Q < 0.10$), while the fixed-effects model was used when there was no obvious heterogeneity ($I^2 < 50\%$ or $P_Q \geq 0.10$). The funnel plot and Begg's test were applied to assess publication bias, and sensitivity analysis was used to test the stability of the analysis results. $p < 0.05$ indicates a significant difference in this study.

Results

Characteristics of eligible studies

Study collection and screening process are shown in Figure 1. After further discussion and consideration of the selected articles, 13 cohort studies published between 2012 and 2019 were selected for further analysis [9,10,26-36]. In total, these 13 studies included 1,740 patients with a mean sample size of 133.8 and a range from 68 to 331. Eleven studies presented data on the association between the TRIM44 protein levels and OS, and four studies presented data on the link between TRIM44 and DFS. In these studies, 12 different kinds of solid tumors were analyzed, including gastric cancer (GC), osteosarcoma, cervical cancer (CC), breast cancer (BC), hepatocellular carcinoma (HCC), endometrial carcinoma (EMC), esophageal cancer (EC), melanoma, testicular germ cell tumor (TGCT), non-small cell lung cancer (NSCLC), intrahepatic cholangiocarcinoma (ICC), and epithelial ovarian cancer (EOC). All primary cancer tissues and adjacent non-tumor tissue samples were collected from patients in Japan and P.R. China. The expression of TRIM44 protein in tissue samples was measured by immunohistochemistry (IHC). All included articles were written in English, and they were of good quality. The basic characteristic information is presented in Table 1.

The correlation between increased TRIM44 expression and OS

Eleven studies involving 1,547 malignancy patients reported the HRs for OS. The pooled results for OS are displayed in Figure 2. High expression of TRIM44 protein in malignant tissues was found to be strongly associated with poor OS (HR=1.94, 95% CI: 1.60-2.35, $p<0.0001$), and the heterogeneity test revealed a mild heterogeneity ($I^2=32.6\%; P_Q=0.139$). The over-expression of TRIM44 could serve as a poor prognostic factor in human malignancies. In addition, for OS, the pooled HR values >1 were consistently calculated in the subgroup meta-analysis stratified by the analysis type, sample size, and cutoff value; thus, indicating a significant difference among the two groups (Table 2).

The correlation between increased TRIM44 expression and DFS

Four studies involving 759 cases investigated the association between TRIM44 expression and DFS. Elevated expression of TRIM44 indicated an inferior DFS outcome, with a combined HR of 2.13 (95% CI 1.24-3.65, $p<0.0001$). The combined result indicated that patients with elevated TRIM44 protein expression had a worse DFS rate compared to patients with lower TRIM44 protein expression (Figure 3).

The correlation between increased TRIM44 expression and clinicopathological parameters

The pooled odds ratios (ORs) were calculated to assess the risk of over-expression of TRIM44 protein under different clinicopathological features (Table 3). Tumors with unfavorable clinicopathological parameters were more frequently associated with overexpression of TRIM44 protein. These parameters included deeper tumor invasion (OR=2.72, 95% CI: 1.73-4.30), poor tumor differentiation (OR=1.78, 95% CI: 1.03-3.09), poor clinical stage (OR=2.75, 95% CI: 2.04-3.71), distant metastasis (OR=10.35, 95% CI: 1.01-106.24), lymph node metastasis (OR=2.69, 95% CI: 1.71-4.24), and tumor recurrence (OR=2.30, 95% CI: 1.34-3.95). However, there
was no significant association between elevated TRIM44 expression and gender (OR=1.00, 95% CI: 0.78-1.29, \( p=0.990 \)) or vascular invasion (OR=2.43, 95% CI: 0.85-6.94, \( p=0.097 \)) in patients.

**TRIM44 expression in different cancer types**

The expression level of TRIM44 mRNA from the GEPIA in different types of cancers was shown in Figure 4. Among them, the expression of TRIM44 mRNA was significantly higher in malignant tissues than in the corresponding normal tissues, including CHOL, DLBC, ESCA, STAD, and THYM (Figure 4).

**Validation of the prognostic value of TRIM44 in human tumors**

In a survival analysis conducted through the GEPIA database, we found that high level of TRIM44 mRNA was shown to be significantly associated with unfavorable OS in patients with LAML, LIHC, MESO, and STAD (Figure 5). However, for patients with CHOL or KIRC, a high level of TRIM44 mRNA in tumor samples indicated favorable OS in these cases (Figure 5). And the significant prognostic value of TRIM44 mRNA in patients with KIRC was also displayed using OSkirc webserver (Figure 6). When combined with all data from 33 different types of malignant tumors in GEPIA, the Kaplan-Meier analysis suggested that cancer patients with a high expression level of TRIM44 exhibited poorer OS, compared with cases expressing a low level of TRIM44 (Figure 7).

For the relationship between TRIM44 mRNA level and DFS in human tumors, overexpression of TRIM44 mRNA could be as an unfavorable prognostic biomarker for DFS in patients with ACC, BLCA, and MESO (Figure 8), but as a favorable predictive factor for DFS in cases with KIRC (Figure 8). And when combined with all tumor data from the GEPIA database, the pooled results showed that cancer patients with a high level of TRIM44 tend to have a poor DFS, although there was no statistical difference (Figure 9).

**Publication bias**

The Begg’s visible plots are shown in Figure 10, and the \( p \)-value of Begg’s test was 0.531 for OS. These results suggested that there was no publication bias in the present meta-analysis.

**Sensitivity analysis**

Figure 11 shows that the pooled results in this meta-analysis were relatively robust.

**Discussion**

Ubiquitination is a post-translational protein modification that tags proteins for proteolytic degradation. It is involved in intercellular biological behavior, such as signal transduction, cell cycle regulation, DNA repair, antigen processing, and apoptosis [37-39]. RING finger ubiquitin E3 ligases have been previously reported to participate in cell-cycle regulation and carcinogenesis in malignancy [40-42]. Recent studies have suggested that some TRIM proteins, which contain a conserved RING finger, B-box, and coiled-coil domains, function as vital regulators of carcinogenesis [1,43,44]. These TRIM family proteins are associated with wide biological phenomena, including cell cycle regulation, transcriptional regulation, apoptosis, and carcinogenesis [45,46].

TRIM-containing protein 44 (TRIM44: 11p13) contains B-box, coiled-coil domains, and a zinc-finger domain, which was discovered in ubiquitin hydrolases [6]. TRIM44 protein and mRNA have been reported to be significantly upregulated in cancer tissues compared to para-cancerous or normal samples. TRIM44 amplification is correlated with unfavorable prognosis and advanced clinicopathological parameters of malignancies [9,12,27]. Increased expression of TRIM44 could promote cell proliferation, migration, and invasion, whereas down-regulation of TRIM44 could significantly inhibit these pathologic features. TRIM44 may act as a cancer-promoting gene regulating deubiquitination and stabilization of oncogenes.

Tumor metastasis is a multistep process that starts with tumor migration and invasion through endothelial barriers via a process known as EMT, which is characterized by loss of cell-cell adhesion and increased cell motility [47-49]. Loss of E-cadherin expression, a hallmark of EMT, has been noted in many malignancies and is associated with increased metastatic potential [50,51]. Cell motility, migration, and invasion are the malignant biological behaviors of cancer cells and the necessary factors for cancer metastasis. Knockdown of TRIM44 inhibited the invasion and migration of human NSCLC cells, and it was associated with the downregulation of mesenchymal markers (such as vimentin and N-cadherin) and upregulation of epithelial markers (such as E-cadherin) [10].
Overexpression of TRIM44 repressed E-cadherin expression and increased vimentin and N-cadherin expression in NSCLC cell lines [10]. Overexpression of TRIM44 induced EMT and increased the metastatic potential of lung cancer cells. In HCC cell lines, it was found that the ectopic expression of TRIM44 dramatically increased the expression of mesenchymal markers N-cadherin and vimentin, but it decreased the expression of epithelial marker E-cadherin; thus, suggesting that overexpression of TRIM44 could potentiate the EMT program [36]. Overexpression of TRIM44 has been shown to induce a similar change in hallmark characteristics of EMT in other cancers, such as ICC and HEC.

Uncontrolled cell proliferation is the biological characteristic of malignant tumors at the cellular level, and abnormal cell cycle regulation is closely related to uncontrolled cell proliferation [50]. TRIM44 expression positively affects the expression of cyclins and CDKs, suggesting that TRIM44 is involved in the regulation of cell cycle G1/s transformation [10,36]. TRIM44 induced cell proliferation in vitro and tumor growth in vivo by accelerating the G1/S transition via the upregulation of cyclins and CDKs. Indeed, ectopic expression of TRIM44 promotes cell proliferation by accelerating the G1/S-phase transition in HCC. In colony formation assays, knockdown of TRIM44 in Huh7 cells significantly decreased the expression levels of cyclin D1 and cyclin E, which have been shown to play a crucial role in accelerating the G1/S-phase transition [36]. p21/p27 was discovered to function as a vital cyclin-dependent kinase inhibitor, and up-regulated expression of p21/p27 can inhibit cell entry into the S phase [52,53]. Knock-down of TRIM44 in glioma cells induces an increase in p21/p27 expression and then it inhibited cell division [54]. Further, the critical p21/p27 regulator AKT is inactivated after TRIM44 is knocked down, but it is activated in glioma cells that overexpress TRIM44 [54].

TRIM44 overexpression leads to high mTOR activity, which is consistent with observations of reduced mTOR signaling in cancer cell lines after siRNA knockdown of TRIM44 [12]. The phosphorylation of downstream mTOR substrates, including p-Akt (Ser473) and p-p70S6K (Thr389), in TRIM44-knockdown cells was markedly inhibited, indicating that TRIM44 functions upstream of the mTOR signaling pathway by phosphorylating mTOR. STAT3 participates in multiple biological behavior regulation, including cell proliferation, apoptosis, and tumorigenesis; and it has been reported to be involved in oncogene regulatory pathways, including AKT/mTOR [55-57].

TRIM44 could function as an E3 ubiquitin ligase and has ubiquitination function. TRIM44 could inhibit the role of AMPK in cells by degrading AMPK [6,58]. AMPK has been reported to inhibit mTOR signaling. The upregulated TRIM44 reduced AMPK activity, thus relieving the inhibition of AMPK in the mTOR signaling pathway, and up-regulating the mTOR signaling from other mechanisms. TRIM44-induced mTOR signaling, EMT, and cyclin/CDK upregulation was reversed by treatment with an inhibitor of the mammalian target of rapamycin (mTOR) [10]. Several previous studies have suggested that MAPK signaling pathways can induce EMT in cancer cells [11,59,60]. Inhibition of MAPK signaling by incubation with a signaling inhibitor significantly repressed ICC cell invasion and metastasis [32]. ERK1/2 has been reported to be involved in the regulation of EMT in ICC cells. TRIM44 could increase the activation of the AKT signaling pathway and activate ERK1/2, thus, suggesting that TRIM44 promotes EMT in ICC cells via the ERK-MAPK pathway.

Furthermore, overexpression of TRIM44 has been reported to be associated with inhibition of apoptosis in esophageal cancer [12]. Microarray analysis showed that TRIM44 knockdown is associated with the dysregulation of NUPR1, CDK19, CADM1, INHBA, TNFSF10, and DDIT4, which could normally activate the apoptotic cell pathways [31]. Bax and Bcl-2 are closely related to apoptosis. Elevated TRIM44 expression significantly repressed Bax and promoted Bcl-2 expression. Thus, TRIM44 has a vital role in inhibiting cellular apoptosis. NF-kB, functioning as a vital nuclear transcription factor, has been reported to be closely related to the inflammatory response, cellular apoptosis, and stress responses. NF-kB is the molecular target of some antitumor drugs [61]. The transcription factor NF-kB has been reported to inhibit apoptosis and to induce drug resistance in cancer cells [62]. Of note, it has been reported that TRIM44 promotes NSCLC development through activation of NF-kB signaling [13]. Previous studies have indicated that cIAP1, c-IAP2, and XIAP are the antiapoptotic transcriptional targets of NF-kB signaling [63]. A previous report has shown that the silencing of TRIM44 could decrease the c-IAP1, c-IAP2, and XIAP expression levels, especially in the presence of doxorubicin [36]. High expression of TRIM44 could enhance the resistance of HCC cells to doxorubicin via accelerating NF-kB activation. Increased NF-kB-mediated transcriptional activity was detected in TRIM44-transfected breast cancer cells [29].

Elevated TRIM44 protein expression enhanced proliferation and migration of TGCT cells, while TRIM44 protein knockdown repressed this biological behavior and promoted cell apoptosis.

Ki67 has been reported to be a promoter of cell proliferation [64]. TRIM44 modulates Ki67 expression and promotes HEC cell proliferation. Amplified TRIM44 expression was also discovered in melanoma tissues, and overexpression of TRIM44 is associated with a malignant phenotype of melanoma [35]. TRIM44 deubiquitinates and stabilizes TOLL-like receptor 4, which activates the
AKT/mTOR pathway and induces cellular EMT. Moreover, miR-26b-5p is the upstream regulatory gene of TRIM44, which acts as a suppressor [35].

We believe that this study is the first meta-analysis to provide a systematic assessment of the prognostic value of TRIM44 in malignancies. Further, we have discussed the possible role of TRIM44 in tumor progression. Pooled results indicated that the TRIM44 protein level could act as a valuable prognostic marker in patients with malignancies. Malignancy patients with increased tissue TRIM44 expression had a significantly shorter OS and a lower DFS rate than patients with low TRIM44 expression. Furthermore, cancer patients with unfavorable clinicopathological parameters more frequently showed overexpression of TRIM44 protein. The GEPIA analysis results showed that TRIM44 was frequently overexpressed in multiple malignant tumors, and cancer patients with increased tissue TRIM44 expression had unfavorable prognosis. TRIM44 was involved in the malignant biological behavior of tumor cells and played an intersection role in the gene regulatory pathways.

However, there are several possible limitations of our research that may interfere with the generalizability of these conclusions. First, more samples need to be included to confirm the reliability of the conclusion. Second, all patients were from Asian countries, and studies including patients from other countries and races are required. Third, HRs and the corresponding 95% CIs were extracted from the survival curves and this might be less accurate than those directly obtained from the studies in multivariate analysis. Also, heterogeneity still exists in some results of clinicopathological characteristics.

Conclusion

The present study demonstrated that the TRIM44 level is correlated with disease progression and prognosis in patients with malignancies. We found that TRIM44 is involved in the malignant biological behavior of tumor cells and it plays an intersection role in the gene regulatory pathways. Therefore, TRIM44 may be an important molecular marker for determining the malignant properties and an attractive therapeutic target for patients with malignancies.

Declarations

Acknowledgments

Not applicable.

Authors' contributions

XGL and YQX initiated and promoted the study. XGL and BZW implemented data analysis and completed the manuscript. Z Y reviewed the data analysis process and proofread the manuscript. All authors have read and approved the manuscript.

Funding

This was an unfunded study.

Availability of data and materials

Meta-analysis is a secondary analysis, in which all data are fully available without restriction and all materials can be found in the included original studies.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
Author Details

1 Department of General Surgery, the First People’s Hospital of Neijiang, Neijiang 641000, Sichuan Province, P. R. China. 2 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou 570100, Hainan Province, P. R. China. 3 Department of medicine, Southwest Medical University, Luzhou 646000, Sichuan Province, P. R. China; Correspondence to Yi Zhang, E-mail: 307910985@qq.com.

Abbreviations

TRIM44: Tripartite motif-containing 44; GEPIA: Gene Expression Profiling Interactive Analysis; TRIM: tripartite motif; USPs: ubiquitin-specific proteases; EMT: epithelial-to-mesenchymal transition; NOS: Newcastle-Ottawa quality assessment scale; ACC: Adrenocortical carcinoma; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangio carcinoma; COAD: Colon adenocarcinoma; DLBC: Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LAML: Acute myeloid leukemia; LGG: Brain lower grade glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenocarcinoma; PAA: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; SARC: Sarcoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; TGCT: Testicular germ cell tumors; THCA: Thyroid carcinoma; THYM: Thymoma; UCEC: Uterine corpus endometrial carcinoma; UCS: Uterine carcinosarcoma; UVM: Uveal melanoma;

GC: gastric cancer; BC: breast cancer; EC: esophageal cancer; EMC: endometrial carcinoma; EOC: epithelial ovarian cancer; ICC: intrahepatic cholangiocarcinoma; NSCLC: non-small cell lung cancer; TGTC: testicular germ cell tumor; HCC: hepatocellular carcinoma; CC: cervical cancer; OS: overall survival; DFS: disease-free survival; NR: not report; M: multivariate analysis; C: curves; IHC: immunohistochemistry; HR: hazard ratio; OR: odds ratio.

References

1 Hatakeyama S. TRIM proteins and cancer. NAT REV CANCER. 2011.

2 Leong PWF, Liew K, Lim W and Chow VTK. Differential Display RT–PCR Analysis of Enterovirus-71-Infected Rhabdomyosarcoma Cells Reveals mRNA Expression Responses of Multiple Human Genes with Known and Novel Functions.; 295(1):147-159.

3 High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. GENE CHROMOSOME CANC. 2008; 47(6):500-509.

4 Boutou E, Matsas R and Mamalaki A. Isolation of a mouse brain cDNA expressed in developing neuroblasts and mature neurons. Brain Research Molecular Brain Research. 2001; 86(1-2):153-167.

5 Yang B, Wang J, Wang Y, Zhou H, Wu X, Tian Z and Sun B. Novel Function of Trim44 Promotes an Antiviral Response by Stabilizing VISA. J IMMUNOL.; 190(7):3613-3619.

6 Urano T, Usui T, Takeda S, Ikeda K, Okada A, Ishida Y, Iwayanagi T, Otomo J, Ouchi Y and Inoue S. TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochemical & Biophysical Research Communications.; 383(2):268.

7 Weissman AM. Regulating protein degradation by ubiquitination. 1997; 18(4):189-198.

8 Toby GG, Gherraby W, Coleman TR and Golemis EA. A Novel RING Finger Protein, Human Enhancer of Invasion 10, Alters Mitotic Progression through Regulation of Cyclin B Levels. Molecular & Cellular Biology. 2003; 23(6):2109-2122.

9 Xiong D, Jin C, Ye X, Qiu B, Jianjun X, Zhu S, Xiang L, Wu H and Yongbing W. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway. CANCER SCI. 2018; 109(10):3080-3092.
10 Xing Y, Meng Q, Chen X, Zhao Y, Liu W, Hu J, Xue F, Wang X and Cai L. TRIM44 promotes proliferation and metastasis in non-small cell lung cancer via mTOR signaling pathway. Oncotarget.; 7(21).

11 Zhang C, Liu LX, Dong ZR, Shi GM, Cai JB, Zhang PF, Ke AW, Yu JX, Zhou J and Fan J. Up-regulation of 14-3-3zeta expression in intrahepatic cholangiocarcinoma and its clinical implications. Tumour Biol. 2015; 36(3):1781-1789.

12 Ong CA, Shannon NB, Ross-Innes CS, O’Donovan M, Rueda OM, Hu DE, Kettunen MI, Walker CE, Noorani A, Hardwick RH, Caldas C, Brindle K and Fitzgerald RC. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. 2014; 106(5).

13 Luo Q, Lin H, Ye X, Huang J, Lu S and Xu L. Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway.

14 Wells G, Shea B and O’Connell J. The Newcastle-Ottawa Scale (NOS) for Assessing The Quality of Nonrandomised Studies in Meta-analyses. Ottawa Health Research Institute Web site. 2014; 7.

15 Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. NUCLEIC ACIDS RES. 2017; 45(W1):W98-W102.

16 Dong H, Wang Q, Li N, Lv J, Ge L, Yang M, Zhang G, An Y, Wang F, Xie L, Li Y, Zhu W, Zhang H, Zhang M and Guo X. OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma. FRONT GENET. 2019; 10:1378.

17 Zhang G, Wang Q, Yang M, Yao X, Qi X, An Y, Dong H, Zhang L, Zhu W, Li Y and Guo X. OSpaad: An online tool to perform survival analysis by integrating gene expression profiling and long-term follow-up data of 1319 pancreatic carcinoma patients. Mol Carcinog. 2020; 59(3):304-310.

18 Yan Z, Wang Q, Sun X, Ban B, Lu Z, Dang Y, Xie L, Zhang L, Li Y, Zhu W and Guo X. OSbrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts. FRONT ONCOL. 2019; 9:1349.

19 Xie L, Wang Q, Nan F, Ge L, Dang Y, Sun X, Li N, Dong H, Han Y, Zhang G, Zhu W and Guo X. OSacc: Gene Expression-Based Survival Analysis Web Tool For Adrenocortical Carcinoma. CANCER MANAG RES. 2019; 11:9145-9152.

20 Wang F, Wang Q, Li N, Ge L, Yang M, An Y, Zhang G, Dong H, Ji S, Zhu W and Guo X. OSuvm: An interactive online consensus survival tool for uveal melanoma prognosis analysis. Mol Carcinog. 2020; 59(1):56-61.

21 Wang Q, Zhang L, Yan Z, Xie L, An Y, Li H, Han Y, Zhang G, Dong H, Zheng H, Zhu W, Li Y, Wang Y and Guo X. OScc: an online survival analysis web server to evaluate the prognostic value of biomarkers in cervical cancer. FUTURE ONCOL. 2019; 15(32):3693-3699.

22 Xie L, Wang Q, Dang Y, Ge L, Sun X, Li N, Han Y, Yan Z, Zhang L, Li Y, Zhang H and Guo X. OSkirc: a web tool for identifying prognostic biomarkers in kidney renal clear cell carcinoma. FUTURE ONCOL. 2019; 15(27):3103-3110.

23 Wang Q, Wang F, Lv J, Xin J, Xie L, Zhu W, Tang Y, Li Y, Zhao X, Wang Y, Li X and Guo X. Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis. ONCOL LETT. 2019; 18(2):1199-1206.

24 Zhang G, Wang Q, Yang M, Yuan Q, Dang Y, Sun X, An Y, Dong H, Xie L, Zhu W, Wang Y and Guo X. OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients. FRONT ONCOL. 2019; 9:466.

25 Wang Q, Xie L, Dang Y, Sun X, Xie T, Guo J, Han Y, Yan Z, Zhu W, Wang Y, Li W and Guo X. OSlms: A Web Server to Evaluate the Prognostic Value of Genes in Leiomyosarcoma. FRONT ONCOL. 2019; 9:190.

26 Li P, Yin H, Meng F, Liu S and Ma R. High TRIM44 expression in endometrial carcinoma is associated with a poorer patient outcome. Pathology - Research and Practice. 2018; 214(5).

27 Kashimoto K, Komatsu S, Ichikawa D, Arita T and Otsuji E. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. CANCER SCI. 2012; 103(11):2021-2026.
28 Kawaguchi T, Komatsu S, Ichikawa D, Hirajima S, Nishimura Y, Konishi H, Shiozaki A, Fujiwara H, Okamoto K and Tsuda H. Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma. Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine.; 39(6):56835656.

29 Hidetaka K, Kotaro A, Kazuhiro I, Ikuko S, Keiichi K, Takeshi F, Akihiko O, Toshiaki S, Kuniko H and Satoshi I. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling. INT J MOL SCI.; 18(9):1931.

30 Wang H, Zi-Ling F, Gong-Hao Z and Xin M. <em>TRIM44</em>, a crucial target of miR-410, functions as a potential oncogene in osteosarcoma. Oncotargets & Therapy.; Volume 11:3637-3647.

31 Yamada Y, Takayama K, Fujimura T, Ashikari D, Obinata D, Takahashi S, Ikeda K, Kakutani S, Urano T and Fukuhara H. A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. CANCER SCI..

32 Peng R, Zhang PF, Zhang C, Huang XY, Ding YB, Deng B, Bai DS and Xu YP. Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med. 2018; 7(3):796-808.

33 Liu S, Meng F, Ding J, Ji H, Lin M, Zhu J and Ma R. High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer. BIOSCIENCE REP..

34 Shuang L, Hexuan Y, Hongying J, Jiaqi Z and Rong M. Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer. EXP THER MED..

35 Wei C, Wang L, Zhu M, Deng X, Wang D, Zhang S, Ying J, Yuan X, Wang Q and Xuan T. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4. J EXP CLIN CANC RES.; 38(1).

36 Zhu X, Wu Y, Miao X, Li C, Yin H, Yang S, Lu X, Liu Y, Chen Y, Shen R, Chen X and He S. High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma. Tumour Biol. 2016; 37(11):14615-14628.

37 Raboy B, Parag HA and Kulka RG. Conjugation of [125I]ubiquitin to cellular proteins in permeabilized mammalian cells: comparison of mitotic and interphase cells. EMBO J.; 5(5):863-869.

38 Fiore PPD, Polo S and Hofmann K. Opinion: When ubiquitin meets ubiquitin receptors: a signalling connection.; 4(6):491-497.

39 Wilkinson KD, Urban MK and Haas AL. Ubiquitin is the ATP-dependent Proteolysis Factor I of rabbit reticulocytes. J BIOL CHEM. 1980; 255(16):7529-7532.

40 Burger and M. A. A Novel RING-Type Ubiquitin Ligase Breast Cancer-Associated Gene 2 Correlates with Outcome in Invasive Breast Cancer. CANCER RES.; 65(22):10401-10412.

41 Shabbeer S, Omer D, Bememan D, Weitzman Q, Alpaugh A, Pietraszkiewicz A, Metsuyanim S, Shainskaya A, Papa MZ and Yarden RI. BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation. ONCOGENE.; 32(42):5005-5016.

42 Ryu YS, Lee Y, Lee KW, Hwang CY, Maeng JS, Kim JH, Seo YS, You KH, Song B and Kwon KS. TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF?)-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP). J BIOL CHEM.; 286(29):25729-25738.

43 Nisole S, Stoye JP and Sa B A. TRIM family proteins: retroviral restriction and antiviral defence.; 3(10):799-808.

44 Di K, Linskey ME and Bota DA. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. ONCOGENE.; 32(42):5038-5047.

45 Ozato K, Shin D, Chang T and Morse HC. TRIM family proteins and their emerging roles in innate immunity. NAT REV IMMUNOL.; 8(11):849-860.

46 McNab FW, Rajsbaum R, Stoye JP and Garra AO. Tripartite-motif proteins and innate immune regulation.; 23(1):46-56.

47 Jou J and Diehl AM. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J CLIN INVEST.; 120(4):1031-1034.
48 Acloque H, Adams MS, Fishwick K, Nieto MA and Bronner-Fraser M. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. CELL. 2009; 119(6):871.

49 Connor KM, Hempel N, Nelson KK, Dabiri G, Gamara A, Belarmino J, Van De Water L, Mian BM and Melendez JA. Manganese Superoxide Dismutase Enhances the Invasive and Migratory Activity of Tumor Cells. CANCER RES.; 67(21):10260-10267.

50 Zeisberg M and Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J CLIN INVEST.; 119(6):1429-1437.

51 Williams GH and Kai S. The cell cycle and cancer. P NATL ACAD SCI USA. 2012; 226(2):352-364.

52 Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL and Eldeiry WS. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21. 1997; 389(6647):187-190.

53 Fillies T, Woltering M, Brandt B, Van Diest J, Werkmeister R, Joos U and Buerger H. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. ONCOL REP.; 17(2):355-359.

54 Zhou X, Yang Y, Ma P, Wang N, Yang D, Tu Q, Sun B, Xiang T, Zhao X and Hou Z. TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.

55 Yu H, Kortylewski M and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. NAT REV IMMUNOL.; 7(1):41-51.

56 Yu C, Meyer D, Campbell G, Larner A, Carter-Su C, Schwartz J and Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. SCIENCE.; 269(5220):81-83.

57 Kortylewski M and Yu H. Stat3 as a Potential Target for Cancer Immunotherapy. J IMMUNOTHER.; 30(2):131-139.

58 Pineda CT and Potts PR. Oncogenic MAGEA-TRIM28 ubiquitin ligase downregulates autophagy by ubiquitinating and degrading AMPK in cancer. AUTOPHAGY.; 11(5):844-846.

59 Santamaria PG and Nebreda AR. Deconstructing ERK Signaling in Tumorigenesis. MOL CELL. 2010; 38(1):3-5.

60 Huang X, Ke A, Shi G, Zhang X, Zhang C, Shi Y, Wang X, Ding Z, Xiao Y and Yan J. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. HEPATOLOGY.; 57(6):2235-2247.

61 Lai Y, Lin VTG, Zheng Y, Benveniste EN and Lin F. The Adaptor Protein TRIP6 Antagonizes Fas-Induced Apoptosis but Promotes Its Effect on Cell Migration. MOL CELL BIOL. 2010; 30(23):5582-5596.

62 Bentires-Alj M, Barbu V, Fillet M, Chariot A and Bours V. NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells. ONCOGENE. 2003; 22(1):90-97.

63 Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP and Kuo ML. Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NFκB-dependent XIAP Up-Regulation. J BIOL CHEM.; 279(23):24015-24023.

64 Scholzen T and Gerdes J. The Ki-67 protein: From the known and the unknown. J CELL PHYSIOL. 2000; 182(3):311-322.

Tables
| Year | Disease | Country | Sample size | Over-expression (N, %) | Detection method | Evaluation standard of TRIM44 overexpression | End-points (analysis type) | Follow-up | NOS score |
|------|---------|---------|-------------|-----------------------|-----------------|-----------------------------------------------|---------------------------|-----------|-----------|
| 2012 | GC      | Japan   | 112         | 28, 25%               | IHC             | Final staining scores\(^1\) \(\geq 4\)       | OS (M)                    | NR        | 8         |
| 2017 | BC      | Japan   | 129         | 67, 52%               | IHC             | Final staining scores\(^1\) \(\geq 5\)       | OS (M) \(\geq 5\) years  | 9         | 9         |
| 2017 | EC      | Japan   | 68          | 39, 57%               | IHC             | Final staining scores\(^2\) \(\geq 1\)       | OS (M) \(\geq 5\) years  | 9         | 9         |
| 2018 | EMC     | China   | 143         | 80, 56%               | IHC             | Final staining scores\(^1\) \(\geq 4\)       | OS (C) \(\geq 5\) years  | 7         | 7         |
| 2018 | EOC     | China   | 109         | 93, 85%               | IHC             | Final staining scores\(^1\) \(\geq 4\)       | OS (M), DFS (M) \(\geq 5\) years | 7         | 7         |
| 2018 | ICC     | China   | 130         | 71, 55%               | IHC             | Percentage of TRIM44 positive cells \(\geq50\%) | OS (M) \(\geq 5\) years  | 8         | 8         |
| 2016 | NSCLC   | China   | 331         | 208, 63%              | IHC             | Final staining scores\(^3\) \(\geq 4\)       | OS (M), DFS (M) \(\geq 5\) years | 9         | Y         |
| 2018 | EC      | China   | 100         | 53, 53%               | IHC             | Final staining scores\(^3\) \(\geq 4\)       | OS (M) \(\geq 5\) years  | 8         | 8         |
| 2017 | TGCT    | Japan   | 103         | 41, 40%               | IHC             | Intensity score \(\geq1\)                     | NR                        | NR        | 7         |
| 2016 | HCC     | China   | 106         | 73, 69%               | IHC             | Final staining scores\(^3\) \(\geq 5\)       | OS (M) \(\geq 5\) years  | 8         | 8         |
| 2019 | CC      | China   | 122         | 81, 66%               | IHC             | Final staining scores\(^1\) \(\geq 3\)       | OS (M), DFS (M) \(\geq 5\) years | 7         | 7         |
| 2019 | Melanoma | China   | 197         | 98, 50%               | IHC             | integrated optical density value \(\geq\) median value | OS (M), DFS (M) \(\geq 5\) years | 7         | 7         |
| 2018 | Osteosarcoma | China | 90          | 53, 58.9%             | IHC             | Final staining scores\(^1\) \(>5\)          | NR                        | NR        | 8         |

\(a\): GC: gastric cancer; BC: breast cancer; EC: esophageal cancer; EMC: endometrial carcinoma; EOC: epithelial ovarian cancer; ICC: intrahepatic carcinoma; NSCLC: non-small cell lung cancer; TGTC: testicular germ cell tumor; HCC: hepatocellular carcinoma; CC: cervical cancer; OS: overall DFS: disease-free survival; NR: not report; M: multivariate analysis; C: curves; IHC: immunohistochemistry; HR: hazard ratio; \(^1\) the intensity score: 0, negative; 1, weak; 2, moderate; 3, strong and percentage of the total cell population (proportion score:0 <10%; 10%\(\leq\)1\(\leq\)33%; 6%; 67%\(\leq\)3\(\leq\)100%); \(^2\) staining intensity was divided into three steps (scores 0, 1, and 2) in the infiltrated region of each case. When score 0 was negative and score 1 and score 2 were positive. \(^3\)TRIM44 staining was evaluated based on intensity scores (0, no staining; 1, weak staining; 2, staining; and 3\(\geq\), strong staining) and percentage scores (0, 0%; 1 \(\leq\)25%; 2, >25\(\leq\)50%; 3, 50\(\leq\)75%; 4, >75%).

Table 1. Characteristics of included studies.
### Table 2. Pooled HR for OS according to the subgroup analysis.

| Categories          | Studies | HR (95% CI) | p-value | Heterogeneity | I² (Model) |
|---------------------|---------|-------------|---------|---------------|------------|
| All                 | 1154    | 1.94 (1.60-2.35) | <0.0001 | 32.6          | 0.139 Fixed |
| Cutoff value for high expression |          |             |         |               |            |
| Final staining scores: 4 or 5 | 1118   | 2.03 (1.42-2.19) | <0.0001 | 40.9          | 0.119 Fixed |
| Final staining scores: 3 | 231     | 4.27 (1.83-9.95) | 0.001   | 0.0           | 0.604 Fixed |
| Others              | 198     | 2.10 (1.44-3.06) | <0.0001 | 0.0           | 0.571 Fixed |

### Analysis type

| Analysis type       | Studies | HR (95% CI) | p-value | Heterogeneity | I² (Model) |
|---------------------|---------|-------------|---------|---------------|------------|
| Multivariate        | 1040    | 1.66 (1.16-2.37) | <0.0001 | 40.9          | 0.139 Fixed |
| Survival curves     | 143     | 8.66 (1.10-68.22) | 0.001   | -             | -          |

### Sample size

| Sample size | Studies | HR (95% CI) | p-value | Heterogeneity | I² (Model) |
|-------------|---------|-------------|---------|---------------|------------|
| ≥100        | 1040    | 1.68 (1.39-2.03) | <0.0001 | 34.0          | 0.115 Fixed |
| <100        | 68      | 2.82 (1.04-9.13) | 0.041   | -             | -          |

### Table 3. Results of the meta-analysis of high TRIM44 and clinicopathological parameters.

| Clinicopathological parameter | Studies | OR (95% CI) | p-value | Heterogeneity | I² (Model) |
|-------------------------------|---------|-------------|---------|---------------|------------|
| Gender (male vs. female)      | 8       | 1.00 (0.78-1.29) | 0.990   | 0.0           | 0.699 Fixed |
| Recurrence (+ vs. -)          | 3       | 2.30 (1.34-3.95) | 0.002   | 14.2          | 0.312 Fixed |
| Tumor depth (T3-4 vs. T1-2)   | 4       | 2.72 (1.73-4.30) | <0.0001 | 0.0           | 0.488 Fixed |
| Lymph node metastasis (+ vs. -) | 10       | 2.69 (1.71-4.24) | <0.0001 | 56.4          | 0.014 Random |
| Distant metastasis (+ vs. -)  | 3       | 10.35 (1.01-106.24) | 0.049   | 90.0          | <0.0001 Random |
| TNM stage (III-IV vs. I-II)   | 7       | 2.75 (2.04-3.71) | <0.0001 | 32.7          | 0.179 Fixed |
| Poorly/undifferentiated vs. well/moderately | 6       | 1.78 (1.03-3.09) | 0.0001 | 62.8          | 0.020 Random |
| Vascular invasion (+ vs. -)   | 3       | 2.43 (0.85-6.94) | 0.097   | 71.7          | 0.029 Random |

**Figures**
Relevant records retrieved through Web of Science, EMBASE, PubMed, CNKI, Wanfang and other available databases. (n=162)

Excluded by title and abstract information. (n=117)

Full text retrieved for eligibility. (n=45)

Excluded by details: studies that did not investigate prognosis, studies not grouped according to the expression levels of TRIM44, and studies without valuable data. (n=32)

Literatures enrolled in this meta-analysis finally. (n=13)

Figure 1

Flowchart depicting the steps of the literature search and selection process.
**Figure 2**

Forest plot of HR for the relationship between increased TRIM44 expression and OS.

| Study ID | HR (95% CI) | Weight |
|----------|-------------|--------|
| Kawabata H | 8.11 (2.09, 47.70) | 1.51 |
| Kashimoto K | 3.37 (1.18, 9.64) | 3.35 |
| Kawaguchi T | 2.82 (1.04, 9.13) | 3.13 |
| Li P | 1.28 (0.08, 21.48) | 0.47 |
| Liu S | 3.66 (1.31, 10.22) | 3.51 |
| Peng R | 2.02 (1.20, 2.66) | 22.95 |
| Xing Y | 1.70 (1.15, 2.50) | 24.41 |
| Xiong D | 2.24 (1.18, 4.25) | 9.03 |
| Zhu X | 3.44 (1.32, 8.99) | 4.01 |
| Liu S | 5.92 (1.33, 26.43) | 1.65 |
| Wei CY | 1.30 (1.04, 2.21) | 25.99 |
| Overall (I-squared = 32.6%, p = 0.139) | 1.94 (1.60, 2.35) | 100.00 |
| Study   | HR (95% CI)   | Weight |
|---------|---------------|--------|
| Liu S   | 4.02 (1.59, 10.19) | 18.27  |
| Xing Y  | 1.74 (1.24, 2.43)  | 34.60  |
| Liu S   | 6.55 (1.88, 22.82) | 12.73  |
| Wei CY  | 1.23 (1.01, 2.01)  | 34.40  |
| Overall (I-squared = 73.0%, p = 0.011) | 2.13 (1.24, 3.65) | 100.00 |

NOTE: Weights are from random effects analysis

Figure 3

Forest plot of HR for the relationship between increased TRIM44 expression and DFS.
Figure 4

TRIM44 mRNA expression in different types of human malignancies.
Figure 5
Kaplan-Meier plotter of OS for 33 types of malignant tumors.
Figure 6

Kaplan-Meier plotter of OS in multiple analysis web servers.
Figure 7

Kaplan-Meier plotter of OS for all cancer patients.
Figure 8

Kaplan-Meier plotter of DFS for 33 types of malignant tumors.
Figure 9

Kaplan-Meier plotter of DFS for all cancer patients.
Figure 10

Publication bias assessment of TRIM44 expression and OS.
Figure 11

Sensitivity analysis of TRIM44 expression and OS.